Anavex Life Sciences Corp (AVXL)

[TrueTrades]

It's only a shelf registration. A final prospectus supplement (424B3) will precede a request by the company for effectiveness.

Now if that has been delayed because of an investigation, that is another matter. That we don't know.

Perhaps there is an unusual delay and that combined with a (possible) SEC investigation spells doom. I'm not qualified to say either way.

I think the $150M figure is the magic number. That is what Missling is looking for in up-front Phase 3 development funds. The S-3 is just a demonstration that we can raise the funds ourselves, if necessary. It also provides publicly-disclosed base prospectus info as part of a non-deal roadshow.

I am also convinced the little redhead did not go to the ball without her suitor waiting and ready. We'd still be OTC.

It's all coming...according to plan.
§